Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nasopharyngeal carcinoma patient samples: radio-sensitive samples vs. radio-resistant samples

ABSTRACT: Expression profiling of nasopharyngeal carcinoma patients comparing radio-sensitive samples with radio-resistant samples.

ORGANISM(S): Homo sapiens

PROVIDER: GSE32389 | GEO | 2013/09/21

SECONDARY ACCESSION(S): PRJNA147935

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Nasopharyngeal carcinoma patient samples: radio-sensitive samples vs. radio-resistant samples

Project description:Expression profiling of nasopharyngeal carcinoma patients comparing radio-sensitive samples with radio-resistant samples. Two condition-experiments, radio-sensitive and radio-resistant nasopharyngeal carcinoma patients. Biological replicates: 8 radio-sensitive, 12 radio-resistant, different donors in the same hospital. One patient per array.

2013-09-21 | E-GEOD-32389 | biostudies-arrayexpress

Comparison of gene expression in radio-resistant and radio-sensitive patient-derived spheroid cultures of small cell carcinoma of the cervix

Project description:We established panels of patient-derived culture of the cancer cells from small cell carcinoma of the cervix uteri (SCCC) by cancer tissue–originated spheroids (CTOS) method. Then we developed in vitro sensitivity assay for radiation using CTOSs to assess the intrinsic radio-sensitivity and mechanism of radio-resistance in individual SCCC patients. To find factors that affect to the radio-sensitivity we compared gene expression of radio-resistant CTOS (cerv-5) and radio-sensitive CTOS (cerv-9).

2014-04-07 | GSE56540 | GEO

Comparison of gene expression in radio-resistant and radio-sensitive patient-derived spheroid cultures of small cell carcinoma of the cervix

Project description:We established panels of patient-derived culture of the cancer cells from small cell carcinoma of the cervix uteri (SCCC) by cancer tissueM-bM-^@M-^Soriginated spheroids (CTOS) method. Then we developed in vitro sensitivity assay for radiation using CTOSs to assess the intrinsic radio-sensitivity and mechanism of radio-resistance in individual SCCC patients. To find factors that affect to the radio-sensitivity we compared gene expression of radio-resistant CTOS (cerv-5) and radio-sensitive CTOS (cerv-9). We compared gene expression of cerv5 and cerv9 CTOSs under the culture condition.

2014-04-07 | E-GEOD-56540 | biostudies-arrayexpress

Microarray analysis of HeLa Parental vs HeLa radio-resistant tumour xenograft in mice

Project description:Analysis of differential gene expression in HeLa Parental vs radio-resistant xenograft tumours. The aim is to identify potential genes that are deregulated in radio-resistant tumours.

2021-07-31 | GSE181080 | GEO

Radiopharmaceuticals enhance CAR T-cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling [scRNA-Seq]

Project description:Chimeric antigen receptor (CAR) T-cell therapy has limited efficacy against solid tumors such as neuroblastoma (NB). Key obstacles include extensive tumor burden and the presence of an immunosuppressive tumor microenvironment (TME). We employ targeted radiopharmaceutical therapy (RPT) using [67Cu]Cu-LLP2A and find that it potentiated the anti-tumor activity of CAR T-cells in radio-sensitive and radio-resistant NB models via distinct mechanisms. In radio-sensitive NB, RPT is directly tumoricidal while also enhancing CAR T-cell efficacy through pro-immune pathways, most notably via the TNFα pathway, leading to paracrine activation of T-cells. In radio-resistant NB, RPT improves CAR T-cells by remodeling the myeloid compartment in the TME and increasing the formation of immunological niches of cytotoxic CD8⁺ GZMB⁺ and CD4⁺ GZMB+ CAR T-cells. While neither treatment modality alone can effectively treat NB, the combination of VLA-4-targeted RPT and GD2 or B7-H3 CAR T-cells augments anti-tumor efficacy, resulting in marked tumor regression in preclinical NB models.

2026-05-18 | GSE330930 | GEO

Radiopharmaceuticals enhance CAR T-cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling [RNA-Seq]

2026-05-18 | GSE330929 | GEO

SARS-CoV-2 Oropharyngeal and Nasopharyngeal samples

Project description:Microbiome analysis of oropharyngeal and nasopharyngeal samples of SARS-CoV-2 infected patients

2021-02-06 | GSE166281 | GEO

Gene expression in radio-sensitive or -resistant breast cancer cells

Project description:Gene expression in radio-sensitive or -resistant breast cancer cells

| PRJNA664100 | ENA

microRNA profile of human nasopharyngeal tissues: nasopharyngeal carcinoma tissues vs. normal nasopharyngeal tissues

Project description:MicroRNAs are biomarkers of prognosis and survival for many types of cancer. We evaluated whether microRNAs can predict the survival and efficacy of concurrent chemotherapy in nasopharyngeal carcinoma (NPC) patients. We retrospectively analyzed microRNA expression in 312 paraffin-embedded NPC specimens and 18 normal nasopharyngeal tissues using microarray. We found Forty-one microRNAs are differentially expressed between NPC and normal tissues, and a five-microRNA signature can predict survival independent of stage. NPC patients with the low-risk microRNA signature have a favorable response to concurrent chemotherapy. microRNA profiling of nasopharyngeal carcinoma tissues vs. normal nasopharyngeal tissues 312 paraffin-embedded nasopharyngeal carcinoma tissues and 18 paraffin-embedded normal nasopharyngeal tissues

2012-06-30 | E-GEOD-32960 | biostudies-arrayexpress

Radiopharmaceuticals enhance CAR T-cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling

Project description:Radiopharmaceuticals enhance CAR T-cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling

| PRJNA1466202 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data